Terminated trial tested combo to outsmart resistant lung cancer
NCT ID NCT05313009
Summary
This early-stage trial tested the safety and effectiveness of combining two drugs, tarloxotinib and sotorasib, for patients with advanced non-small cell lung cancer driven by a specific genetic change called KRAS G12C. The study was for patients whose cancer had continued to grow despite previous treatment with a similar targeted therapy. The goal was to see if blocking two pathways at once could overcome the cancer's resistance and control the disease better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Conditions
Explore the condition pages connected to this study.